Porton Biologics ranks among China’s potential unicorn companies in 2021

On June 29,the Report on China’s Potential Unicorn Companies in 2021 was released. Porton Biologics, a professional CDMO company in gene and cell therapy , was listed in the report

Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs

Portonbio announced a strategic cooperation with KAEDI .Portonbio will offer CMC services for KAEDI’s CAR-T cell therapies with its end-to-end CDMO platform for gene and cell therapies to help accelerate their development process.

Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy

On April 16, 2021, Suzhou Porton Biologics Ltd., which focuses on gene and cell therapy CDMO service, officially announced the closing of Series A funding round, which raised 400 million RMB. The participants of the financing include industry's top-tier investment institutions, SDIC and GL Ventures, HM Capital, Huashan Ruilian and Momentum Venture.

Porton Biologics will attend the BioPharmaceutical Innovation Technology Summit 2021

TheBioPharmaceuticalInnovationTechnologySummit2021willbeheldatCrownePlazaShanghaiPujiangon9-10th,April.OurboothnumberisD1.WelcometoattendtheconferenceandseminarsessiongivenbyPortonBiologics.

Serum-free Suspension Lentivirus Production Platform Assists with the Development of Cell Therapy Drugs

Serum-freeSuspensionLentivirusProductionPlatformofPortonbioischaracterizedbyhighvirustransfectiontiter,animal-freecomponents,andhighvirustransfectiontiterrecoveryduringpurification,lowmanufacturingcos

Porton Biologics has published an important AAV research in Molecular Therapy

Recently,Dr.DamienMarsicfromProtonBiologicsLtd.hasachievedanimportantscientificresultsinthemodificationandscreeningofAAV.ThearticleEngineeringandinvitroselectionofanovelAAV3Bvariantwithhighhepatocytet